M+W appointed to deliver a £55m specialist cell and gene threapy centre in Stevenage
M+W Group has been appointed to deliver a £55m manufacturing centre for the production of cell and gene therapy products.
The centre in Stevenage’s Bioscience Catalyst campus is being developed by Cell Therapy Catapult.
The building will be used to produce products for late phase clinical trials and commercial supply of advanced therapeutic medicinal products, including cell and gene therapies. Completion is expected in 2017.
Keith Thompson, chief executive of the Cell Therapy Catapult, said: “The manufacturing centre will provide global scientific and medical communities with the assistance they need to convert research into products that have the potential to have a direct impact in advanced healthcare.”
Spencer Baber, managing director M+W Group UK said: “We are proud to be associated with a government funded project of this specific nature which will see the UK established as the leading centre for the development of new and innovative medicinal products for the treatment of debilitating diseases such as blindness, diabetes and cancer.”